Literature DB >> 11160326

Formation of high-affinity C5 convertases of the alternative pathway of complement.

N Rawal1, M Pangburn.   

Abstract

Cleavage of C5 by C5 convertase is the last enzymatic step in the complement activation cascade leading to the formation of the cytolytic proteolytically activated form of C5 (C5b)-9 complex. In the present study, we examined the effect of the density of C3b (the proteolytically activated form of C3) on the function of the noncatalytic subunit of natural surface-bound forms of the enzyme. A comparison of the kinetic parameters of C5 convertases assembled on three surfaces (zymosan, rabbit erythrocytes, and sheep erythrocytes) were similar and revealed that the average K:(m) decreased approximately 28-fold (5.2-0.18 microM) when the density of C3b was increased from approximately 18,000 to 400,000 C3b/cell. Very-high-affinity C5 convertases were generated when preformed C3 convertases were allowed to self amplify by giving them excess C3. These convertases exhibited K(m) from 0.016 to 0.074 microM, well below the normal plasma concentration of C5 in blood (0.37 microM). The results suggest that in serum convertases formed with monomeric C3b will be relatively inefficient in capturing C5 but will continue to cleave C3 opsonizing the cell surface for phagocytosis, whereas convertases formed with C3b-C3b complexes in areas of high C3b density will primarily cleave C5. The catalytic rate of these convertases approaches maximum velocity, thereby switching the enzyme from cleavage of C3 to cleavage of C5, and production of the cytolytic C5b-9 complex.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11160326     DOI: 10.4049/jimmunol.166.4.2635

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  33 in total

1.  The human complement receptor type 2 (CR2)/CR1 fusion protein TT32, a novel targeted inhibitor of the classical and alternative pathway C3 convertases, prevents arthritis in active immunization and passive transfer mouse models.

Authors:  Masha Fridkis-Hareli; Michael Storek; Eran Or; Richard Altman; Suresh Katti; Fang Sun; Tao Peng; Jeff Hunter; Krista Johnson; Yi Wang; Ante S Lundberg; Gaurav Mehta; Nirmal K Banda; V Michael Holers
Journal:  Mol Immunol       Date:  2018-12-01       Impact factor: 4.407

2.  The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation.

Authors:  M Harboe; G Ulvund; L Vien; M Fung; T E Mollnes
Journal:  Clin Exp Immunol       Date:  2004-12       Impact factor: 4.330

3.  Convertase inhibitory properties of Staphylococcal extracellular complement-binding protein.

Authors:  Ilse Jongerius; Brandon L Garcia; Brian V Geisbrecht; Jos A G van Strijp; Suzan H M Rooijakkers
Journal:  J Biol Chem       Date:  2010-03-19       Impact factor: 5.157

4.  Structural basis for inhibition of complement C5 by the SSL7 protein from Staphylococcus aureus.

Authors:  Nick S Laursen; Natasha Gordon; Stefan Hermans; Natalie Lorenz; Nicola Jackson; Bruce Wines; Edzard Spillner; Jesper B Christensen; Morten Jensen; Folmer Fredslund; Mette Bjerre; Lars Sottrup-Jensen; John D Fraser; Gregers R Andersen
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-04       Impact factor: 11.205

5.  Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation.

Authors:  Markus J Harder; Nadine Kuhn; Hubert Schrezenmeier; Britta Höchsmann; Inge von Zabern; Christof Weinstock; Thomas Simmet; Daniel Ricklin; John D Lambris; Arne Skerra; Markus Anliker; Christoph Q Schmidt
Journal:  Blood       Date:  2016-12-27       Impact factor: 22.113

6.  Inhibition of the Complement Alternative Pathway by Chemically Modified DNA Aptamers That Bind with Picomolar Affinity to Factor B.

Authors:  Xin Xu; Chi Zhang; Dalton T Denton; Daniel O'Connell; Daniel W Drolet; Brian V Geisbrecht
Journal:  J Immunol       Date:  2021-01-08       Impact factor: 5.422

7.  Structural basis for therapeutic inhibition of complement C5.

Authors:  Matthijs M Jore; Steven Johnson; Devon Sheppard; Natalie M Barber; Yang I Li; Miles A Nunn; Hans Elmlund; Susan M Lea
Journal:  Nat Struct Mol Biol       Date:  2016-03-28       Impact factor: 15.369

8.  Spatiotemporal dynamics of complement C5a production within bacterial extracellular polymeric substance.

Authors:  Erin C Conrad; Yueh-Ya Hsu; David M Bortz; John G Younger
Journal:  J Innate Immun       Date:  2013-01-11       Impact factor: 7.349

9.  Brain microvascular endothelial cells exhibit lower activation of the alternative complement pathway than glomerular microvascular endothelial cells.

Authors:  Sarah E Sartain; Nancy A Turner; Joel L Moake
Journal:  J Biol Chem       Date:  2018-03-19       Impact factor: 5.157

10.  Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor.

Authors:  Suzan H M Rooijakkers; Jin Wu; Maartje Ruyken; Robert van Domselaar; Karel L Planken; Apostolia Tzekou; Daniel Ricklin; John D Lambris; Bert J C Janssen; Jos A G van Strijp; Piet Gros
Journal:  Nat Immunol       Date:  2009-06-07       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.